Target Name: LOC101928824
NCBI ID: G101928824
Review Report on LOC101928824 Target / Biomarker Content of Review Report on LOC101928824 Target / Biomarker
LOC101928824
Other Name(s): Uncharacterized LOC101928824, transcript variant X2 | Uncharacterized LOC101928824, transcript variant X1 | uncharacterized LOC101928824 | LOC101928824 variant X1 | LOC101928824 variant X2

LOC101928824: A novel drug target or biomarker

LOC101928824 is a protein that is located in the endoplasmic reticulum (ER) and is involved in the regulation of protein stability and degradation. The ER is a complex organelle that is responsible for the quality control and degradation of proteins that have been synthesized in the cytoplasm. LOC101928824 is a small molecule that interacts with the protein known as heat shock protein (HSP) also known as stress-protein-1 (SP1).

HSP1 is a highly conserved protein that is found in all eukaryotic cells. It is involved in a variety of cellular processes, including stress responses, DNA repair, and protein stability. LOC101928824 is a novel protein that has been identified using transcript variant analysis as a potential drug target or biomarker.

The search for potential drug targets or biomarkers is an important step in the development of new pharmaceuticals. Drug targets are proteins that are involved in a specific cellular process and are potential targets for drugs to interact with and modulate their activity. Biomarkers are proteins that are derived from biological sources and can be used as indicators of disease or other biological processes.

LOC101928824 is a protein that is expressed in most tissues and cells of the body. It is highly conserved and has a similar structure to other HSPs, including SP1. LOC101928824 is involved in the regulation of protein stability and degradation, which is a critical process that is involved in the quality control of proteins.

In recent years, researchers have identified numerous drug targets that are involved in various diseases, including cancer, neurodegenerative diseases, and respiratory diseases. LOC101928824 is one of these proteins that is being targeted as a potential drug target.

The discovery of LOC101928824 as a potential drug target or biomarker has important implications for the development of new pharmaceuticals. If LOC101928824 is successfully targeted, it could lead to the development of new treatments for various diseases. Additionally, LOC101928824 could also be used as a biomarker for diseases, such as cancer, neurodegenerative diseases, and respiratory diseases.

LOC101928824 is a small molecule that has been shown to interact with HSP1. Studies have shown that LOC101928824 can form a stable complex with HSP1, which is involved in the regulation of protein stability and degradation. This interaction between LOC101928824 and HSP1 suggests that they may be involved in a common process.

Furthermore, LOC101928824 has been shown to be regulated by several different factors, including stress, UV radiation, and reactive oxygen species (ROS). These factors could be potential drug targets or biomarkers that could be used to modulate the activity of LOC101928824.

In conclusion, LOC101928824 is a novel protein that has been identified as a potential drug target or biomarker. Its interaction with HSP1 and its regulation by stress, UV radiation, and ROS suggests that it may be involved in a process that is relevant to protein stability and degradation. Further research is needed to determine if LOC101928824 is indeed a valid drug target or biomarker, and if so, what the best way to target it is

Protein Name: Uncharacterized LOC101928824

The "LOC101928824 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC101928824 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LOC101928832 | LOC101928834 | LOC101928844 | LOC101928847 | LOC101928849 | LOC101928859 | LOC101928861 | LOC101928864 | LOC101928890 | LOC101928893 | LOC101928894 | LOC101928911 | LOC101928912 | LOC101928923 | LOC101928940 | LOC101928947 | LOC101928948 | LOC101928950 | LOC101928972 | LOC101929003 | LOC101929048 | LOC101929073 | LOC101929085 | LOC101929098 | LOC101929106 | LOC101929129 | LOC101929130 | LOC101929133 | LOC101929174 | LOC101929200 | LOC101929208 | LOC101929219 | LOC101929237 | LOC101929256 | LOC101929258 | LOC101929268 | LOC101929279 | LOC101929298 | LOC101929309 | LOC101929372 | LOC101929401 | LOC101929418 | LOC101929419 | LOC101929439 | LOC101929452 | LOC101929457 | LOC101929460 | LOC101929470 | LOC101929485 | LOC101929491 | LOC101929506 | LOC101929532 | LOC101929536 | LOC101929551 | LOC101929555 | LOC101929563 | LOC101929578 | LOC101929615 | LOC101929622 | LOC101929633 | LOC101929698 | LOC101929707 | LOC101929710 | LOC101929713 | LOC101929718 | LOC101929727 | LOC101929755 | LOC101929761 | LOC101929762 | LOC101929772 | LOC101929788 | LOC101929996 | LOC101930053 | LOC101930071 | LOC101930098 | LOC101930112 | LOC101930129 | LOC101930496 | LOC102723311 | LOC102723313 | LOC102723321 | LOC102723323 | LOC102723340 | LOC102723341 | LOC102723342 | LOC102723345 | LOC102723364 | LOC102723370 | LOC102723376 | LOC102723403 | LOC102723409 | LOC102723439 | LOC102723446 | LOC102723475 | LOC102723490 | LOC102723493 | LOC102723517 | LOC102723536 | LOC102723553 | LOC102723560